The Clinical Impact of Infection with Swine Flu (H1N109) Strain of Influenza Virus in Hematopoietic Stem Cell Transplant Recipients

Department of Haematology, Level II ICPMR, Westmead Hospital, Westmead, NSW 2145, Australia.
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation (Impact Factor: 3.4). 01/2011; 17(1):147-53. DOI: 10.1016/j.bbmt.2010.07.004
Source: PubMed


There are limited data on the impact of H1N109 infection in patients undergoing hematopoietic stem cell transplantation (HSCT). We reviewed individual medical records of patients who underwent HSCT or were on follow-up post-HSCT between May and September 2009. Thirteen patients with H1N109 infection were identified: 2 <100 days post-HSCT, 7 >100 days post-HSCT, and 4 just prior to HSCT. Five (38.7%) had lower respiratory tract involvement (LRTI), whereas the remainder had upper respiratory tract involvement (URTI). LRTI occurred in patients who were profoundly neutropenic post-HSCT or on potent immunosuppression for chronic graft-versus-host disease (cGVHD). At 100 days post-H1N109 infection, only 1 patient with LRTI survived, whereas all with URTI are alive. Four patients successfully treated for H1N109 infection prior to HSCT underwent the procedure after 4 to 6 weeks without any complications. Another 6 patients received oseltamivir prophylaxis during conditioning and none developed H1N109 infection. In conclusion, H1N109 infection was associated with LRTI in HSCT recipients who were profoundly neutropenic or immunosuppressed. Prior H1N109 infection did not affect the successful outcome of HSCT and oseltamivir prophylaxis in a small group of recipients resulted in no infection. Further studies are required.

Download full-text


Available from: Patricia E Ferguson, Nov 10, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: The authors have developed a novel method for ventricular tachycardia (VT) source localization using body surface potential mapping (BSPM). Kohonen self-organizing maps (SOM) are utilized for the classification of different types of VTs. The method is a two-step process. First, a large number of potential patterns from VT QRS complexes are presented to the SOM. Second, QRS time traces on this SOM are created to find the representative patterns for different types of VT. The localization can be performed using these time traces as a reference. The presented method utilizes both spatial and temporal aspects of the recorded VT to create a representative pattern of the tachycardia. The data was obtained from 27 patients with ventricular tachycardia; 21 were used for the teaching set and 6 for the test set. Results comparable to the well-documented integral map method were obtained in this study
    Engineering in Medicine and Biology Society, 1997. Proceedings of the 19th Annual International Conference of the IEEE; 01/1997
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Seroconversion rates following influenza vaccination in patients with hematologic malignancies after hematopoietic stem cell transplantation (HSCT) are known to be lower compared to healthy adults. The aim of our diagnostic study was to determine the rate of seroconversion after 1 or 2 doses of a novel split virion, inactivated, AS03-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HSCT recipients ( Identifier: NCT01017172). Blood samples were taken before and 21 days after a first dose and 21 days after a second dose of the vaccine. Antibody (AB) titers were determined by hemagglutination inhibition assay. Seroconversion was defined by either an AB titer of ≤ 1:10 before and ≥ 1:40 after or ≥ 1:10 before and ≥ 4-fold increase in AB titer 21 days after vaccination. Seventeen patients (14 allogeneic, 3 autologous HSCT) received 1 dose and 11 of these patients 2 doses of the vaccine. The rate of seroconversion was 41.2% (95% confidence interval [CI] 18.4-67.1) after the first and 81.8% (95% CI 48.2-97.7) after the second dose. Patients who failed to seroconvert after 1 dose of the vaccine were more likely to receive any immunosuppressive agent (P = .003), but time elapsed after or type of HSCT, age, sex, or chronic graft-versus-host disease was not different when compared to patients with seroconversion. In patients with hematologic malignancies after HSCT the rate of seroconversion after a first dose of an adjuvanted H1N1 influenza A vaccine was poor, but increased after a second dose.
    Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 02/2011; 17(10):1546-50. DOI:10.1016/j.bbmt.2011.02.004 · 3.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: S.H. Lee, H. Cheuh, K.H. Yoo, Y.J. Kim, K.W. Sung, H.H. Koo, D.H. Kim, S.J. Kim, K. Kim, J.H. Jang, C.W. Jung. Hematopoietic stem cell transplantation from a related donor infected with influenza H1N1 2009. Transpl Infect Dis 2011. All rights reserved.
    Transplant Infectious Disease 02/2011; 13(5):548-50. DOI:10.1111/j.1399-3062.2011.00616.x · 2.06 Impact Factor
Show more